Ethnic minority groups less informed about cancer symptoms
the ONA take:
According to new findings presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, United Kingdom, ethnic minorities in England were less informed about cancer symptoms and were less likely to see a doctor when they thought they had a possibly serious symptom.
Researchers at King's College London in London, United Kingdom, analyzed about 50,000 responses from the Cancer Research UK Cancer Awareness Measure, a national population-based survey to investigate levels of cancer awareness. Researchers found that people with a black ethnic background were half as likely as white people to identify unexplained bleeding as a possible cancer symptom.
People of South Asian descent were a one-fourth as likely as white people to identify an explained lump as a possible cancer symptom. In addition, people with South Asian backgrounds were more likely to report embarrassment and low confidence to discuss their symptoms with their doctor, while white people were more concerned about wasting the physician's time.
The findings suggest that more public awareness is needed to help people identify cancer symptoms earlier in disease progression and that people need to be encouraged to discuss unexplained changes in their body with their physician.
Ethnic minorities less informed about cancer symptoms and less likely to see a doctor.
Ethnic minorities in England are less aware of cancer symptoms and more likely to say they wouldn't see the doctor, even when they have a symptom that they think might be serious, according to research being presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
Researchers looked at nearly 50,000 responses to the Cancer Research UK Cancer Awareness Measure* from people across England. They found that ethnic minority groups were consistently less aware of cancer symptoms.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|